Company: MIRA
Filing Date: 2025-05-08
Form Type: 8-K
Source: 0001641172-25-009155
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-05-08
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

On
April 30, 2025, the Board of Directors of MIRA Pharmaceuticals, Inc. (“ MIRA” or the “ Company”) unanimously approved
a definitive agreement to acquire SKNY Pharmaceuticals, Inc. (“ SKNY”), a privately held biotechnology company developing
therapies targeting obesity and nicotine dependence. The acquisition follows the completion of independent third-party valuations conducted
by Moore Financial Consulting, which assigned SKNY an enterprise value of approximately $30.5 million and MIRA an enterprise value of
approximately $30 million.

As
part of the transaction, SKNY shall contribute an amount of assets or cash (or a combination of the two) totaling $5,000,000 to MIRA
at closing, with no contingencies. This capital infusion is expected to enhance MIRA’s balance sheet and support future development
initiatives.

The
combined enterprise value of over $60 million creates a stronger, more diversified platform positioned to address multiple high-value
markets with significant unmet need. The Company believes this transaction strengthens its strategic position by integrating complementary
assets, expanding its pipeline, and enhancing long-term shareholder value.

MIRA
is preparing to file a preliminary proxy statement on Form 14A with the U. S. Securities and Exchange Commission (SEC) to seek shareholder
approval of the transaction.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                          MIRA PHARMACEUTICALS, INC.                               
  Dated: May 8, 2025      By:                             /s/                      
                          Name:                           Erez Aminov              
                          Title:                          Chief Executive Officer